AGENUS INC

AGEN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
261
SEC Filings

Business Summary

PART I Item 1. B usiness Our Business Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy. Our lead clinical program is botensilimab (BOT or AGEN1181), alone and in combinat...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAGENdiscussed_in_filing Cybersecurity
topic_mentionAGENdiscussed_in_filing Regulation
topic_mentionAGENdiscussed_in_filing Cybersecurity
topic_mentionAGENdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001193125-26-108632EDGAR100K words
2025-03-172024-12-310000950170-25-040289EDGAR—
2024-03-142023-12-310000950170-24-031620EDGAR—
2023-03-162022-12-310000950170-23-008517EDGAR—
2022-03-012021-12-310001564590-22-007867EDGAR—
2021-03-162020-12-310001564590-21-013619EDGAR—
2020-03-162019-12-310001564590-20-011221EDGAR—
2019-03-182018-12-310001564590-19-008311EDGAR—
2018-03-162017-12-310001564590-18-006093EDGAR—
2017-03-162016-12-310001564590-17-004618EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-274554EDGAR27K words
2025-08-112025-06-300000950170-25-106633EDGAR—
2025-05-122025-03-310000950170-25-069396EDGAR—
2024-11-122024-09-300000950170-24-125608EDGAR—
2024-08-082024-06-300000950170-24-093937EDGAR—
2024-05-072024-03-310000950170-24-053951EDGAR—
2023-11-092023-09-300000950170-23-062051EDGAR—
2023-08-082023-06-300000950170-23-039768EDGAR—
2023-05-092023-03-310000950170-23-019649EDGAR—
2022-11-082022-09-300000950170-22-022915EDGAR—
2022-08-092022-06-300001564590-22-028592EDGAR—
2022-05-102022-03-310001564590-22-019080EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001193125-26-125170EDGAR1K words
2026-03-160001193125-26-107288EDGAR—
2026-01-160001193125-26-014678EDGAR—
2026-01-140001193125-26-012922EDGAR—
2026-01-080001193125-26-007706EDGAR—
2025-11-100001193125-25-273266EDGAR—
2025-10-090001193125-25-235819EDGAR—
2025-09-230001193125-25-213574EDGAR—
2025-08-110000950170-25-106235EDGAR—
2025-06-200000950170-25-088502EDGAR—

261 total filings indexed. 229 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc. ABOS — Acumen Pharmaceuticals, Inc.

Company Identity

CIK0001098972
TickerAGEN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 1b55ec1d07343e4b66c868c0cec5e3a8277610e3df679229feaebe0ab0af1525
parent: fd5e5fefe55068a8de92f1d716a5f6f21c29d37c09d1327dfe70f28644c6a49e
content hash: 3ab057f4f8c8dc1ab0ae1b50818aee408d381bbef538c28c963d437e4de0e8e5
signed: 2026-04-13T04:43:30.912Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf